Research &
Development

Our rigorous R&D expertise allows us to come up with complex generics of niche and challenging formulations. We adhere to globally accredited GMP and GLP standards. Established in the year 2006, our R&D unit specializes in developing various specialty generics and innovative solutions across oncology and other segments.
Our state-of-the-art R&D division received prestigious approval from Department of Scientific and Industrial Research (DSIR) in 2011, marking a significant milestone in our commitment to innovation and excellence.

Our R&D activities
include:

Innovative Drug Development

Pioneering bio-equivalence studies and New Drug Delivery Systems (NDDS).

Global Market
Ready

Seamless technology transfer and formulation development for international production.

Quality-Driven
Research

Conducting stability studies and adhering to GMP & GLP documentation standards.

Optimized Manufacturing Processes

We ensure efficiency and excellence in executing pilot batches and scaling up production.

Cutting-Edge Pre-Formulation Studies

Comprehensive compatibility, solubility, and excipient evaluations.

Versatility in Formulations

Expertise in developing generic, patented, and bioequivalent drugs for regulated and non-regulated markets.

Sterile Product Expertise

Advanced capabilities in sterile pharmaceutical solutions.

Collaboration for Excellence

Close coordination with manufacturing units for innovative global product offerings.

R&D Pipeline in Action

50+

New molecules under development

30+

New products
launched